Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic ...

New preclinical research shows a promising drug combination that targets ovarian cancer’s survival pathways, paving the way ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Initially used for blood glucose control, the medications reduce cardiovascular events and mitigate heart failure hospitalization, regardless of diabetes status.

Patients with rheumatoid arthritis treated with Janus kinase inhibitors do not demonstrate increased risks for major cardiovascular complications vs. TNF inhibitors or other biologic disease ...

DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase inhibitor to have made it into the clinic.

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 ...

On June 3, 2025, the industry's first proof-of-concept clinical validation of AI-driven drug discovery was published in Nature Medicine. Insilico Medicine and collaborators reported promising safety ...

Conclusions: Overall, dual inhibition of HER2 and VEGF without chemotherapy is a promising therapeutic strategy for patients with breast cancer, especially those with HER2-overexpressing breast cancer ...